Valuation: Amphastar Pharmaceuticals, Inc.

Market Cap 86Cr 74Cr 70Cr 64Cr 119.67Cr 8.19TCr 121.59Cr 821.3Cr 320.64Cr 4.1TCr 322.28Cr 315.3Cr 14TCr P/E 2026 *
9.3x
P/E 2027 * 7.64x
Enterprise Value 116.18Cr 100.71Cr 94Cr 86Cr 161.97Cr 11TCr 164.56Cr 1.11TCr 433.97Cr 5.55TCr 436.19Cr 426.74Cr 19TCr EV / Sales 2026 *
1.55x
EV / Sales 2027 * 1.33x
Free-Float
47.23%
Yield 2026 *
-
Yield 2027 * -
1 day+1.00%
1 week+1.87%
Current month+1.20%
1 month+4.61%
3 months+10.15%
6 months-29.19%
Current year-24.65%
1 week 19.55
Extreme 19.55
20.9
1 month 18.5
Extreme 18.5
22.64
Current year 16.64
Extreme 16.645
29.52
1 year 16.64
Extreme 16.645
31.26
3 years 16.64
Extreme 16.645
65.92
5 years 16.64
Extreme 16.645
67.66
10 years 12.05
Extreme 12.05
67.66
Manager TitleAgeSince
Chief Executive Officer 79 29/02/1996
Chief Operating Officer 76 29/02/1996
Director of Finance/CFO 58 01/04/2014
Director TitleAgeSince
Chairman 76 29/02/1996
Director/Board Member 79 29/02/1996
Director/Board Member 58 04/08/2022
Date Insider Type Main position Quantity % Market Cap.
11/08/26 Sell

Director

-7,973 0.0181%
07/08/26 Fiscal year

Chief Financial Officer

18,286 0.0415%
09/07/26 Free

Director

24,532 0.0556%
Change 5-day change 1-year change 3-year change Capi.($)
+1.00%+1.87%-33.79%-63.10% 86Cr
-0.92%+1.43%+83.05%+128.86% 1,07800Cr
+0.47%+1.98%+50.26%+50.75% 63TCr
+0.83%+2.85%+24.49%+64.82% 44TCr
-1.09%-2.56%+43.10%+35.13% 36TCr
-0.79%-2.70%+24.36%+34.82% 29TCr
-1.27%-2.93%-0.33%+3.90% 25TCr
+0.40%+3.21%+44.42%+59.17% 23TCr
+1.40%-1.11%-7.03%-51.28% 20TCr
+1.67%+5.56%+14.98%+72.68% 17TCr
Average +0.16%+1.48%+24.35%+33.57% 36.45TCr
Weighted average by Cap. -0.17%+1.30%+45.42%+65.44%

Financials

2026 *2027 *
Net sales 75Cr 65Cr 61Cr 55Cr 104.24Cr 7.14TCr 105.91Cr 715.42Cr 279.3Cr 3.57TCr 280.73Cr 274.65Cr 12TCr 78Cr 68Cr 64Cr 58Cr 109.35Cr 7.49TCr 111.1Cr 750.49Cr 292.99Cr 3.75TCr 294.49Cr 288.11Cr 13TCr
Net income 9.93Cr 8.61Cr 8.07Cr 7.36Cr 14Cr 947.9Cr 14Cr 95Cr 37Cr 474.49Cr 37Cr 36Cr 1.58TCr 12Cr 10Cr 9.38Cr 8.55Cr 16Cr 1.1TCr 16Cr 110.43Cr 43Cr 551.42Cr 43Cr 42Cr 1.84TCr
Net Debt 30Cr 26Cr 25Cr 22Cr 42Cr 2.9TCr 43Cr 290.3Cr 113.33Cr 1.45TCr 113.91Cr 111.45Cr 4.84TCr 18Cr 16Cr 15Cr 14Cr 26Cr 1.76TCr 26Cr 176.18Cr 69Cr 879.72Cr 69Cr 68Cr 2.93TCr
Logo Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient (API) products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. The Company manufactures and sells over 25 prescription pharmaceutical products, and one over-the-counter product, Primatene MIST. Its marketed products include BAQSIMI (glucagon) nasal powder 3mg, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone, Cortrosyn, Amphadase, and Epinephrine injection. It manufactures and sells two API products: Recombinant Human Insulin (RHI API) and porcine insulin API. It is also focused on generic and proprietary product candidates in the injectable, inhalable, topical, and intranasal markets.
Employees
1,976
Date Price Change Volume
13/26/13 $20.18 +1.00% 5,26,116
12/26/12 $19.98 -2.15% 3,43,843
11/26/11 $20.42 +0.54% 5,70,493
10/26/10 $20.31 -2.26% 6,45,749
07/26/07 $20.78 +4.90% 13,00,994
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
20.18USD
Average target price
22.00USD
Spread / Average Target
+9.02%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AMPH Stock